-
Express treatment of pancreatic cancer, Amgen KRAS inhibitor achieves 84% disease control rate
Time of Update: 2022-03-06
▎WuXi AppTec Content Team Editor A few days ago, Amgen announced the latest efficacy and safety results of its KRAS G12C inhibitor, Lumarkras (sotorasib), in the treatment of patients with advanced pancreatic cancer harboring KRAS G12C mutations .
-
Liver Cancer: Response to Lenvatinib (Lenvatinib) Initial Treatment is a Prognostic Indicator for Lenvatinib (LEN) + Transarterial Chemoembolization (LEN-TACE) Sequential Therapy
Time of Update: 2022-03-05
Therefore, a study was recently published in the journal Liver Cancer, mainly to compare the efficacy and safety of LEN-TRAE sequential therapy with LEN monotherapy in patients with unresectable hepatocellular carcinoma (u-HCC), and to explore the impact Factors of deep response to LEN-TRAE sequential therapy .
-
Interpretation of the update points of "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer 2021"
Time of Update: 2022-03-05
The Chinese Society of Clinical Oncology (CSCO) updates the "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer" every year based on the latest research progress .
-
Gastric Cancer: Aspirin and long-term survival after gastric adenocarcinoma surgery
Time of Update: 2022-03-05
Studies have shown that low-dose aspirin use may reduce cancer morbidity and mortality, but its effect on survival in gastric adenocarcinoma is unclear .
A foreign team conducted a related study to evaluate whether taking aspirin after gastrectomy for gastric adenocarcinoma could improve long-term survival .
-
How to pathologically evaluate the efficacy of neoadjuvant therapy for lung cancer?
Time of Update: 2022-03-05
To provide a reliable basis for further clinical treatment and prognosis prediction, pathologists and clinicians jointly formulated the "Expert Consensus on Pathological Evaluation of the Efficacy of Neoadjuvant Therapy for Non-Small Cell Lung Cancer (NSCLC) (2021 Edition)" .
-
Target Oncol: Real-world evaluation of the efficacy and safety of abiraterone plus prednisone or prednisolone (AAP) in first- or second-line treatment of metastatic castration-resistant prostate cancer (mCRPC)
Time of Update: 2022-03-05
Recently, Targeted Oncology published data from a real-world study evaluating the safety and efficacy of AAP as a first- and second-line [post-docetaxel (AAP-PD) only] treatment of patients with mCRPC .
-
Science Advances: mRNA technology enters new field: used to treat fractures and bone defects, promote bone regeneration
Time of Update: 2022-03-05
Recently, researchers from the Mayo Clinic in the United States published a research paper entitled: Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2 in the journal Science Advances .
-
BMC Cancer: Evaluating the efficacy of a weekly low-dose bevacizumab combination regimen in patients with platinum-resistant ovarian cancer
Time of Update: 2022-03-05
In conclusion, the study shows that weekly low-dose bevacizumab combination therapy improves the prognosis of patients with platinum-resistant ovarian cancer compared with monthly high-dose bevacizumab, which needs further verification in the future .
-
J Clin Oncol: The Impact of Anti-Racist Interventions on Racial Disparities in Lung Cancer Surgery
Time of Update: 2022-03-05
In conclusion, the study shows that anti-racism interventions are associated with promoting timely surgery in patients with early-stage lung cancer, helping to reduce racial disparities in timely surgery .
-
Clinical trial of CAR-T cell therapy ATA2271 suspended due to patient death
Time of Update: 2022-03-05
CAR-TThe MSK Phase I clinical study enrolled 27 patients, 25 with malignant pleural mesothelioma (MPM), 1 with metastatic lung cancer , and 1 with metastatic breast cancer , who had received 3 prior treatment regimens , The purpose of this study was to evaluate the safety and potential antitumor activity of mesothelin-targeted autologous CAR-T cell therapy .
-
Gastric Cancer: D1/D2 and CRITICS study to explore the response and prognosis of different molecular subtypes of gastric cancer to neoadjuvant chemotherapy post hoc
Time of Update: 2022-03-05
In resectable gastric cancer, patients with the MSI-high subtype have a favorable prognosis compared with the EBV-/MSS subtype, both in those treated with surgery, and in those receiving perioperative chemotherapy (radiation) in treated patients .
-
Cancer Treat Rev: Immune pk chemotherapy, first-line treatment for advanced urothelial carcinoma
Time of Update: 2022-03-05
Overall survival with IO vs chemotherapy in cisplatin-intolerant patientsPatients who could not be treated with cisplatin also had comparable overall survival with IO (n=509 [49%]) or other chemotherapeutic agents (n=530 [51%]), with a 24-month ΔRMST of only 0.
-
JAMA Oncol: Capecitabine maintenance therapy significantly improves survival in patients with metastatic nasopharyngeal carcinoma
Time of Update: 2022-03-05
In conclusion, for patients with metastatic nasopharyngeal carcinoma who achieved disease control after induction chemotherapy with capecitabine-containing regimen, capecitabine maintenance therapy can significantly prolong event-free survival with controllable side effects .
-
Eur Urol: Association between age, prostate cancer risk and higher Gleason score in a long-term screening program
Time of Update: 2022-03-05
Diagnostic ScreeningPrevious studies have suggested a possible association between older age, increased risk of prostate cancer (PC), and higher Gleason scores .
The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the G ö teborg-1 Prostate Cancer Screening Trial .
-
Hepatology: Dynamic risk prediction of recurrence after radical hepatectomy for hepatocellular carcinoma
Time of Update: 2022-03-05
Compared to single-event time-to-event estimates, multi-state modeling provides more realistic predictions of clinical outcomes after hepatectomy for patients with hepatocellular carcinoma by accounting for multiple postoperative disease states and transitions between them.
-
2022 EANM Guidelines: Intraarterial Radioactive Compounds for the Treatment of Liver and Metastatic Liver Cancers
Time of Update: 2022-03-05
In February 2022, the European Association for Nuclear Medicine (EANM) published guidelines for the treatment of liver and metastatic liver cancer with intra-arterial radioactive compounds .
Primary liver cancer is one of the most common cancers worldwide, yet only 10%-20% of patients can receive treatment .
-
NEJM: Addition of pembrolizumab before and after surgery significantly improves survival in early-stage triple-negative breast cancer
Time of Update: 2022-03-04
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab combined with chemotherapy, plus postoperative adjuvant pembrolizumab, significantly improved event-free productivity compared with neoadjuvant chemotherapy alone .
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab combined with chemotherapy, plus postoperative adjuvant pembrolizumab, significantly improved event-free productivity compared with neoadjuvant chemotherapy alone .
-
European Radiology: How to use CT to predict EMT molecular subtypes of gastric cancer?
Time of Update: 2022-03-04
Figure ROC curve of EMT molecular subtype gastric cancer prediction model and ROC curve of 1000 bootstrap samples .
Figure ROC curve of EMT molecular subtype gastric cancer prediction model and ROC curve of 1000 bootstrap samples .
-
European Radiology: Application of dual-energy CT in benign and malignant nasal lesions
Time of Update: 2022-03-04
Blood vesselRecently, a study published in the journal European Radiology explored the value of DECT in distinguishing benign and malignant sinus lesions by comparing simulated SECT, conventional MRI and DWI, and provided a reference for accurate diagnosis of sinus lesions .
-
Transl Lung Cancer Res: A randomized phase II study comparing the efficacy of bevacizumab combined with different platinum-based chemotherapy regimens in the treatment of advanced non-squamous non-small cell lung cancer (nsNSCLC)
Time of Update: 2022-03-04
Studies have shown that CisPem combined with Bev is more effective than CarPacBev in improving PFS in patients with advanced non-small cell lung cancer .
Studies have shown that CisPem combined with Bev is more effective than CarPacBev in improving PFS in patients with advanced non-small cell lung cancer .
